Lastly, a new oral GnRH antagonist (relugolix) was evaluated in a phase 3 trial involving men with advanced PCa and showed promising results, with a 54% lower risk of major adverse cardiovascular events compared to agonist GnRH [28]. The gene discussed is GNRH1; the disease is posterior cortical atrophy.